Skip to main content
SpringerLink
Log in

Trabectedin

ET 743, Ecteinascidin 743, Yondelis

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Jimeno J, Villalona-Calero M, Eckhardt G, et al. Phase I and pharmacokinetic study of ET-743, a novel minor groove binder of marine origin on a daily x 5 schedule. 34th Annual Meeting of the American Society of Clinical Oncology 17: 191, 16 May 1998

    Google Scholar 

  2. Hillebrand MJX, Jimeno J, Bowman A, et al. Pharmacokinetics of Ecteinascidin-743 in three phase I studies. Annals of Oncology 9 (Suppl 2): 119, 1998

    Google Scholar 

  3. Taamma A, Riofrio M, Beijnen JH, et al. Ecteinascidin-743 24 hour continuous intravenous infusion phase I study in solid tumors patients. 89th Annual Meeting of the American Association for Cancer Research 323, 28 Mar 1998

    Google Scholar 

  4. Beijen JH, Rosing H, Cvitkovic E, et al. Pharmacokinetics and pharmacodynamics of ET-743 (ecteinascidin-743) in phase I trials. 35th Annual Meeting of the American Society of Clinical Oncology 18: 163, 15 May 1999

    Google Scholar 

  5. Twelves C, Hoeckman H, Bowman A, Beijnen JH, Faber JH, et al. A phase I and pharmacokinetic study of ET-743 evaluating a 3 hours intravenous infusion in patients with solid tumors. Clinical Cancer Research. 5 (Suppl): 3790–3791, Nov 1999. ECSG/EORTC, Glasgow, UK; PharmaMar, Madrid, Spain

    Google Scholar 

  6. Twelves CJ, Vermorken J, Bowman A, Early Clinical Studies Group of the EORTC, et al. Phase I and pharmacokinetic study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days. European Journal of Cancer Part A. 33 (Suppl 8): 245, Sep 1997

    Article  Google Scholar 

  7. Bowman A, Twelves C, Hoekman K, et al. Phase I clinical and pharmacokinetic study of ecteinascidin-743 given as a one hour infusion every 21 days. Annals of Oncology 9 (Suppl 2): 118, 1998

    Google Scholar 

  8. Delaloge S, Riofrio M, Brain E, Cottu P, Taamma A, et al. Ecteinascidin in heavily pretreated refractory sarcomas: preliminary evidence of activity. European Journal of Cancer 35 (Suppl 4): 271 (plus poster), Sep 1999

    Article  Google Scholar 

  9. Zelek L, Yovine A, Brain E, Jimeno J, Taamma A, et al. Ecteinascidin-743 in taxane/anthracycline pretreated advanced/ metastatic breast cancer patients: preliminary results with the 24 hour continuous infusion Q3week schedule. 36th Annual Meeting of the American Society of Clinical Oncology 19: 149, 20 May 2000

    Google Scholar 

  10. Le Cesne A, Blay J, Judson I, Van Oosterom A, Verweij J, et al. ET-743 is an active drug in adult soft-tissue sarcoma: a STBSG-EORTC phase II trial. 37th Annual Meeting of the American Society of Clinical Oncology. 20: 353, Part 1, 12 May 2001

    Google Scholar 

  11. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. European Journal of Cancer 37: 97–105, Jan 2001

    Article  PubMed  CAS  Google Scholar 

  12. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clinical Cancer Research 7: 185–191, Jan 2001

    PubMed  CAS  Google Scholar 

  13. Hendriks HR, Fiebig HH, Giavazzi R, et al. ET743, a marine natural product with high antitumour activity in human tumor xenograft models. Annals of Oncology 7 (Suppl 1): 33, 1996

    Google Scholar 

  14. Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clinical Cancer Research 4: 1977–1983, Aug 1998

    PubMed  CAS  Google Scholar 

  15. Ghielmini M, Colli E, Erba E, et al. In vitro cytotoxicity of Ecteinascidin 743 against human hemopoietic progenitors and cancer cells. Annals of Oncology 9 (Suppl 2): 139, 1998

    Google Scholar 

  16. Ghielmini M, Colli E, Erba E, et al. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743). Annals of Oncology 9: 989–993, Sep 1998

    Article  PubMed  CAS  Google Scholar 

  17. Erba E, Bergamaschi D, Ronzoni S, et al. Mode of action of Ecteinascidin 743, a natural marine compound with antitumoral activity. Annals of Oncology 9 (Suppl 2): 139, 1998

    Google Scholar 

  18. Izbicka E, Lawrence R, Davidson K, et al. Incomplete crossresistance between Ecteinascidin-743 and standard chemotherapeutic agents against primary tumors in human tumor cloning assay. Annals of Oncology 9 (Suppl 2): 34, 1998

    Google Scholar 

  19. Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Annals of Oncology 9: 981–987, Sep 1998

    Article  PubMed  CAS  Google Scholar 

  20. Gorfajn BD, Jin S, Hu Z, Scotto KW. ET743, a novel transcription- targeted cehmotherapeutic that inhibits activation of the MDR1 promoter by multiple inducers. 91st Annual Meeting of the American Association for Cancer Research 41: 804, Mar 2000. Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Google Scholar 

  21. PharmaMar. Aplidin (APL) and Yondelis (ET-743), PharmaMar’s two lead anti-tumour agents, show encouraging results. Media Release: 23 Oct 2002. Available from URL: http://www.pharmamar.es

    Google Scholar 

  22. Taamma A, Misset JL, Delaloge S, Guzman C, Di Palma M, et al. Ecteinascidin-743 in heavily pretreated refractory sarcomas: early results of the French experience. Clinical Cancer Research 5 (Suppl): 3791, Nov 1999

    Google Scholar 

  23. PharmaMar. Drug derived from marine organisms continues to show favorable results in cancer trials. Media Release: [2 pages], 23 May 2000. Available from URL: http://www.pharmamar.com

    Google Scholar 

  24. Demetri GD, Seiden M, Garcia-Carbonero R, Supko J, Harmon D, et al. Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: summary of 3 U.S.- based phase II trials. 36th Annual Meeting of the American Society of Clinical Oncology. 19: 553, 20 May 2000

    Google Scholar 

  25. Demetri G, Garcia-Carbonero R, Harmon D, Seiden M, Jimeno J, et al. Ecteinascidin-743 induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phase II trials. Annals of Oncology 11 (Suppl 4): 126, 2000

    Google Scholar 

  26. Le Cesne A, Judson I, Radford J, Blay J-Y, Van Oosterom A, et al. Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: a STBSG-EORTC trial. Annals of Oncology. 11 (Suppl 4): 126, 2000

    Google Scholar 

  27. PharmaMar. Marine-derived ET-743 may increase survival for cancer patients — promising development in treatment of sarcoma. Media Release: [4 pages], 14 May 2001. Available from URL: http://www.pharmamar.com

    Google Scholar 

  28. PharmaMar. PharmaMar reinforces company commitment to improving cancer care by holding a satellite symposium on soft tissue sarcoma (STS) and the clinical benefits of Yondelis (ET-743). Media Release: 22 Oct 2002. Available from URL: http://www.pharmamar.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trabectedin. Drugs in R&D 4, 75–81 (2003). https://doi.org/10.2165/00126839-200304010-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304010-00016

Keywords

Search

Navigation